Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients

被引:10
|
作者
Ojeh, Bazim V. [1 ]
Abah, Isaac O. [2 ]
Ugoagwu, Placid [1 ]
Agaba, Patricia A. [3 ]
Agbaji, Oche O. [4 ]
Gyang, Steven S. [5 ]
机构
[1] Jos Univ, Teaching Hosp, AIDS Prevent Initiat Nigeria APIN, PMB 2076, Jos, Nigeria
[2] Jos Univ, Teaching Hosp, Pharm Dept, PMB 2076, Jos, Nigeria
[3] Univ Jos, Dept Family Med, PMB 2084, Jos, Nigeria
[4] Univ Jos, Jos Univ Teaching Hosp, Dept Med, PMB 2076, Jos, Nigeria
[5] Univ Jos, Dept Pharmacol, PMB 2084, Jos, Nigeria
来源
GERMS | 2018年 / 8卷 / 02期
关键词
Renal impairment; TDF; nephrotoxicity; antiretroviral agents;
D O I
10.18683/germs.2018.1133
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction The use of tenofovir disoproxil fumarate (TDF) in the treatment of HIV infection has been associated with renal dysfunction. In Nigeria, data on the incidence and risk factors of TDF nephrotoxicity is sparse. We determined the cumulative incidence of and risk factors for TDF-induced renal impairment in HIV-infected individuals accessing care at the antiretroviral therapy (ART) clinic of Jos University Teaching Hospital, Nigeria. Methods This retrospective cohort analysis included patients aged 16 years that initiated ART between January 2008 and December 2011. Renal impairment, defined as glomerular filtration rate GFR <60 mL/min/1.73 sqm using the Modification of Diet in Renal Disease (MDRD) equation was assessed at baseline and at 48 weeks on ART. Logistic regression was performed to determine factors associated with incident renal impairment. Results The mean age was 39 +/- 9 years, and 67.1% were female. The cumulative incidence of renal impairment among the TDF-exposed and TDF-unexposed groups was 4.6% and 2.3% respectively (p<0.001). TDF exposure was significantly associated with renal impairment [OR=2.0, 95%CI=(1.48-2.89), p<0.001] in bivariate analysis. In multivariate analysis, older age (aOR=1.06, 95%CI=(1.05-1.08), p<0.001), TDF exposure [aOR=1.85, 95%CI=(1.31-2.60), p<0.001] and co-morbidities [aOR=2.71, 95%CI=(1.72-4.25), p<0.001] were significantly associated with renal impairment. Conclusion TDF exposure, aging and comorbidities were predictors of renal toxicity among HIV positive patients. Regular monitoring of renal function in such high-risk individuals is recommended.
引用
收藏
页码:67 / 76
页数:10
相关论文
共 46 条
  • [1] Tenofovir disoproxil fumarate-induced distal renal tubular acidosis: A case report
    Salimi, Rozhin
    Begum, Ishmath
    Varma, Danturulu Muralidhar
    Nandakrishna, B.
    Rajesh, Radhakrishnan
    Vidyasagar, Sudha
    INTERNATIONAL JOURNAL OF STD & AIDS, 2020, 31 (03) : 276 - 279
  • [2] Mitochondrial pathway of apoptosis and necrosis contribute to tenofovir disoproxil fumarate-induced renal damage in rats
    Ramamoorthy, H.
    Abraham, P.
    Isaac, B.
    Selvakumar, D.
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2019, 38 (03) : 288 - 302
  • [3] Population Pharmacokinetic Simulations for Dose Optimization of Tenofovir Disoproxil Fumarate in HIV-Infected Patients with Moderate-to-Severe Renal Impairment
    Boonpeng, Apinya
    Singkham, Noppaket
    Wutthikul, Chanadda
    Rattanakul, Thanawan
    Weeket, Pinmanee
    Saengpraphanan, Chananan
    Plaengnok, Rungrawin
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, : 424 - 432
  • [4] Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors
    Pontrelli, Giuseppe
    Cotugno, Nicola
    Amodio, Donato
    Zangari, Paola
    Tchidjou, Hyppolite K.
    Baldassari, Stefania
    Palma, Paolo
    Bernardi, Stefania
    BMC INFECTIOUS DISEASES, 2012, 12
  • [5] Determinants of Risk Factors for Renal Impairment among HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate-Based Antiretroviral Regimen in Southern Vietnam
    Hoang, Cuong Q.
    Nguyen, Hai D.
    Vu, Huy Q.
    Nguyen, Khai T.
    Hoang, Linh T.
    Ly, Hong
    Tat, Thang D.
    Phan, Lan T.
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [6] Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy
    Nishijima, Takeshi
    Kurosawa, Takuma
    Tanaka, Noriko
    Kawasaki, Yohei
    Kikuchi, Yoshimi
    Oka, Shinichi
    Gatanaga, Hiroyuki
    AIDS, 2016, 30 (10) : 1563 - 1571
  • [7] Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults
    Agbaji, Oche O.
    Abah, Isaac O.
    Ebonyi, Augustine O.
    Gimba, Zumnan M.
    Abene, Esla E.
    Gomerep, Simji S.
    Falang, Kakjing D.
    Anejo-Okopi, Joseph
    Agaba, Patricia A.
    Ugoagwu, Placid O.
    Agaba, Emmanuel I.
    Imade, Godwin E.
    Sagay, Atiene S.
    Okonkwo, Prosper
    Idoko, John A.
    Kanki, Phyllis J.
    JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2019, 18
  • [8] Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate
    Campbell, Lucy
    Barbini, Birgit
    Burling, Keith
    Cromarty, Ben
    Hamzah, Lisa
    Johnson, Margaret
    Jones, Rachael
    Samarawickrama, Amanda
    Williams, Deborah
    Winston, Alan
    Post, Frank A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (02) : 214 - 219
  • [9] Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients
    Yang, Junyang
    Chen, Jun
    Ji, Yongjia
    Tang, Qi
    Zhang, Renfang
    Liu, Li
    Shen, Yinzhong
    Xun, Jingna
    Song, Wei
    Tang, Yang
    Wang, Zhenyan
    Qi, Tangkai
    Lu, Hongzhou
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 83 : 64 - 71
  • [10] Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate
    Hamzah, L.
    Jose, S.
    Booth, J. W.
    Hegazi, A.
    Rayment, M.
    Bailey, A.
    Williams, D. I.
    Hendry, B. M.
    Hay, P.
    Jones, R.
    Levy, J. B.
    Chadwick, D. R.
    Johnson, M.
    Sabin, C. A.
    Post, F. A.
    JOURNAL OF INFECTION, 2017, 74 (05) : 492 - 500